About Medicenna

Medicenna is a clinical stage immunooncology company advancing novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines™ and first in class Empowered Cytokines™. We are developing a unique set of tunable Superkines™ that can be fused with pro-apoptotic proteins to precisely deliver potent cell-killing agents to cancer cells, the immunosuppressive tumor micro-environment and cancer stem cells without harming healthy cells.

Therapeutic Areas

Autoimmune disorders Oncology

Technologies

Biologics

Company Type

Biotechnology – Therapeutics

State of Ownership

Public

Sponsorship Group

Networker

Influencer Of

Topics

Editions participated in:

September 2018